Blueprint Medicines Reports First Quarter 2023 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls almost 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Blueprint Medicines (BPMC) Tops Q1 EPS by 50c
May 4, 2023 7:47 AM EDTBlueprint Medicines (NASDAQ: BPMC) reported Q1 EPS of ($2.15), $0.50 better than the analyst estimate of ($2.65). Revenue for the quarter came in at $63.3 million versus the consensus estimate of $41.85 million.
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
... More